2025-05-04
Rising Cancer Trends Post-2021: A Call for Investigation
A Freedom of Information response from United Lincolnshire Hospitals NHS Trust (FOI 884/24, 28 April 2025) highlights concerning trends in advanced cancer diagnoses and mortality. From 2017-2020, 2,760 patients were diagnosed with Stage 3 or 4 cancers (any type), with 811 (29.4%) dying within 12 months. From 2021-2024, diagnoses increased to 3,170, with 1,429 (45.0%) deaths—a 76.2% rise in mortality rate. Notably, colorectal cancer cases among postpartum women under 45 surged by 171.4%, from 7 cases (2017-2020, 0 deaths) to 19 cases (2021-2024, 1-4 deaths within 12 months, 5.3%-21.1% mortality). These trends, exemplified by Sharon Plummer’s and Rachel Partin’s rapid-onset Stage 4 colorectal cancers diagnosed post-2021, raise concerns about potential mRNA vaccine safety, supported by emerging research on vaccine contaminants like SV40 and spike protein (Speicher, 2023). Biopsy analyses for Sharon and Rachel are ongoing to investigate possible links, amplified by postpartum immune changes. A follow-up FOI (30 April 2025) seeks vaccination status and genetic data to further explore these trends. We are engaging with the MHRA, awaiting further responses on tumor testing and transparency, to honor Sharon, Rachel, and others. This data underscores the urgent need for independent batch testing and expanded research into mRNA vaccine safety, particularly for pregnant and postpartum women.
2025-05-13
Biopsy Analysis Raises Questions on mRNA Vaccine Safety
A research analysis of Rachel Partin’s Stage 4 colorectal cancer tumor, conducted by INMODIA (Institut für Molekulare Diagnostik, April 2025), detected plasmid ORI and spike protein, raising concerns about potential mRNA vaccine safety. Rachel, diagnosed in February 2023, three weeks postpartum, and passing in March 2024, developed rapid-onset cancer post-2021, prompting investigation into vaccine contaminants. The INMODIA reports, using PCR and immunohistochemistry for research purposes, found ORI, suggesting possible plasmid DNA presence, and spike protein without nucleocapsid, indicating vaccine-related incorporation rather than SARS-CoV-2 infection. No SV40, neomycin cassette, or spike sequence fragments were detected. These findings, supported by emerging research on vaccine contaminants (Speicher, 2023), are not diagnostic and require further validation due to the use of experimental methods. The results align with ongoing biopsy analyses for Sharon Plummer and a follow-up FOI (30 April 2025) seeking vaccination and genetic data, as well as broader trends of rising colorectal cancer in postpartum women under 45 (FOI 884/24, 2021-2024). We are engaging with the MHRA, awaiting further responses on tumor testing and transparency, to honor Rachel, Sharon, and others. This report underscores the need for independent batch testing and expanded research into mRNA vaccine safety for postpartum women.
2025-05-04
Estimated Onset of Sharon Plummer’s Colorectal Cancer: July 2021
A detailed report estimates the onset of Sharon Plummer’s colorectal cancer (Stage 4, diagnosed September 20, 2023, died October 21, 2023) as July 2021, based on medical records (June 2022–October 2023, United Lincolnshire Hospitals NHS Trust) and genetic testing (Nottingham University Hospitals). The analysis identifies two tumor-specific APC mutations driving her sporadic 6 cm sigmoid tumor with liver metastases. Using June 2023 inflammation (ALP 163 U/L, Hb 99 g/L), December 2022 pain, and May 2023 bleeding, it applies the adenoma-carcinoma sequence (Journal of Clinical Oncology, 2018) to back-calculate 1.5–2 years. July 2021 aligns with a 171.4% postpartum cancer surge (FOI 884/24) and her mRNA vaccinations (May/July 2021), raising concerns about potential triggers. Awaiting biopsy results to explore vaccine-related factors, limited pre-2023 data and rapid progression require further validation. This report supports ongoing investigations into postpartum cancer trends and vaccine safety.